US-based biotechnology company Soligenix has begun enrolling subjects in its double-blind, multi-centre Phase III trial of HyBryte (synthetic hypericin), a first-in-class photodynamic therapy for ...
The confirmatory Phase 3 study (Fluorescent Light Activated Synthetic Hypericin 2, FLASH2), builds on the On Monday, Soligenix, Inc. (NASDAQ:SNGX) said it has opened patient enrollment for its ...
The United States Cutaneous Lymphoma Consortium is a multidisciplinary society of physicians which use collaborative research and education to improve the quality of life and prognosis of patients ...
Soligenix (SNGX) , a late-stage biopharmaceutical company focused on rare diseases, announced that its lead investigators will present findings from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback